Our studies suggest that the increased susceptibility of COVID-19 patients to delirium is attributable to the known effect of the virus inducing high levels of circulating IL-6—and that blocking IL-6 activity in the blood may ameliorate delirium. The gene discussed is IL6; the disease is COVID-19.